Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma

Digestive and Liver Disease

Volumn 43, Issue 11, 2011, Pages 912-916

  Brixi Benmansour, Hedia ^a   Jouve, Jean Louis ^b   Mitry, Emmanuel ^c,g   Bonnetain, Franck ^d   Landi, Bruno ^e   Hentic, Olivia ^f   Bedenne, Laurent ^b   Cadiot, Guillaume ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔPITAL DU BOCAGE   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f BEAUJON HOSPITAL   (France)

^g LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

5 Fluorouracile; Chemotherapy; Irinotecan; Neuroendocrine tumour; Prospective; Survival

Indexed keywords

CHROMOGRANIN A; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KI 67 ANTIGEN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MALE; MELENA; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RHABDOMYOLYSIS; STOMACH PERFORATION; SURVIVAL TIME; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; WELL DIFFERENTIATED PANCREATIC ENDOCRINE CARCINOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 80052940064     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.07.001     Document Type: Article

References (33)

1. Yao J.C., Hassan M., Phan A., et al. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
2. Halfdanarson T.R., Rubin J., Farnell M.B., et al. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 2008, 15:409-427.
3. Strosberg J., Nasir A., Coppola D., et al. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009, 40:1262-1268.
4. Yao K.A., Talamonti M.S., Nemcek A., et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001, 130:677-682.
5. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003, 197:29-37.
6. Kianmanesh R., Sauvanet A., Hentic O., et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 2008, 247:659-665.
7. Elias D., Goéré D., Leroux G., et al. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 2009, 35:1092-1097.
8. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992, 326:519-523.
9. Delaunoit T.H., Ducreux M., Boige V., et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?. Eur J Cancer 2004, 40:515-520.
10. Cheng P.N.M., Saltz L.B. Failure to confirm major objective antitumor activity for streptozotocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999, 86:944-948.
11. McCollum A.D., Kulke M.H., Ryan D.P., et al. Lack of efficacy of streptozotocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004, 27:485-488.
12. Ducreux M.P., Boige V., Leboulleux S., et al. Phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas. Oncology 2006, 7:134-140.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
14. Histological typing of endocrine tumours. World Health Organization. International histological classification of tumours 2000, Springer, Genève. 2nd ed. E. Solcia, G. Klöppel, L.H. Sobin (Eds.).
15. Rindi G., Klöppel G., Alhman H., et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
16. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
17. Panzuto F., Di Fonzo M., Iannicelli E., et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 2006, 17:461-466.
18. Arnold R., Rinke A., Klose K.J., et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005, 3:761-771.
19. Raymond E., Dahan L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:501-513.
20. Strosberg J.R., Fine R.L., Choi J., et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011, 117:268-275.
21. Turner N.C., Strauss S.J., Sarker D., et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010, 102:1106-1112.
22. Walter T., Bruneton D., Cassier P.A., et al. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. Clin Colorectal Cancer 2010, 9:248-254.
23. Kouvaraki M.A., Ajani J.A., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004, 22:4762-4771.
24. Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:514-523.
25. Douillard J.Y., Cunningham D., Navarro M., et al. Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000, 355:1040-1047.
26. O'Dwyer P.J., Catalano R.B. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006, 24:4534-4538.
27. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
28. Marion-Audibert A.M., Barel C., Gouysse G., et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003, 125:1094-1104.
29. Couvelard A., O'Toole D., Turley H., et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005, 92:94-101.
30. Yao J.C., Phan A., Hoff P.M., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26:1316-1323.
31. Kulke M.H., Stuart K., Earle C., et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2006, 24(Suppl. 18). Abstract 4044.
32. Venook A.P., Ko A.H., Tempero M.A., et al. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 2008, 26(Suppl. 15). Abstract 15545.
33. Rinke A., Müller H.H., Schade-Brittinger C., et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27:4656-4663.